Balances hidrológicos y estimación de caudales extremos en la Amazonia.

Se estimaron caudales medios y extremos en la cuenca del río Amazonas usando balances hidrológicos de largo plazo y escalamiento estadístico de procesos hidrológicos. En el cálculo de estos balances se considera la variabilidad e espacial de los campos hidrológicos. Se construyeron mapas de la media y la desviación estándar de los caudales máximos y mínimos anuales sobre la red de drenaje del río Amazonas, considerando 6 métodos de estimación de la evaporación real: Choudhury, Coutagne, Morton, Penman, Turc y Zhang, y regionalizando para 6 cuencas: Amazonas, Solimoes, Madeira, Negro, Xingu y Tapajos

Balance de energía y (cuasi-)ciclo hidrológico en el Mundo de las Margaritas.

Se modifica el modelo del Mundo de las Margaritas, con el propósito de incorporar 2 elementos importantes: (1) Considerar la presencia de nubes y el efecto invernadero natural, (2) involucrar de manera parcial el ciclo hidrológico, con el propósito de acoplar la dinámica de las nubes, la biota y el clima, en un sistema gobernado por el balance energético. Se obtienen soluciones de la evolución temporal de la temperatura planetaria, de las poblaciones de Margaritas y de la cobertura de nubes, a partir de las cuales es posible describir acoplamientos fundamentales entre estos subsistemas, lo cual sugiere la validez del modelo

The habitable zone of inhabited planets

ABSTRACT: In this paper we discuss and illustrate the hypothesis that life substantially alters the state of a planetary environment and therefore, modifies the limits of the HZ as estimated for an uninhabited planet. This hypothesis lead to the introduction of the Habitable Zone for Inhabited planets (hereafter InHZ), defined here as the region where the complex interaction between life and its abiotic environment is able to produce plausible equilibrium states with the necessary physical conditions for the existence and persistence of life itself. We support our hypothesis of an InHZ with three theoretical arguments, multiple evidences coming from observations of the Earth system, several conceptual experiments and illustrative numerical simulations. Conceptually the diference between the InHZ and the Abiotic HZ (AHZ) depends on unique and robust properties of life as an emergent physical phenomenon and not necesarily on the particular life forms bearing in the planet. Our aim here is to provide conceptual basis for the development of InHZ models incorporating consistently life-environment interactions. Although previous authors have explored the effects of life on habitability there is a gap in research developing the reasons why life should be systematically included at determining the HZ limits. We do not provide here definitive limits to the InHZ but we show through simple numerical models (as a parable of an inhabited planet) how the limits of the AHZ could be modified by including plausible interactions between biota and its environment. These examples aim also at posing the question that if limits of the HZ could be modified by the presence of life in those simple dynamical systems how will those limits change if life is included in established models of the AHZ

Scaling properties reveal regulation of river flows in the Amazon through a “forest reservoir”

ABSTRACT: Many natural and social phenomena depend on river flow regimes that are being altered by global change. Understanding the mechanisms behind such alterations is crucial for predicting river flow regimes in a changing environment. Here we introduce a novel physical interpretation of the scaling properties of river flows and show that it leads to a parsimonious characterization of the flow regime of any river basin. This allows river basins to be classified as regulated or unregulated, and to identify a critical threshold between these states.We applied this framework to the Amazon river basin and found both states among its main tributaries. Then we introduce the “forest reservoir” hypothesis to describe the natural capacity of river basins to regulate river flows through land–atmosphere interactions (mainly precipitation recycling) that depend strongly on the presence of forests. A critical implication is that forest loss can force the Amazonian river basins from regulated to unregulated states. Our results provide theoretical and applied foundations for predicting hydrological impacts of global change, including the detection of early-warning signals for critical transitions in river basins

Estimación de la recarga en una zona tropical mediante un modelo iterativo.

Se presenta la aplicación de un método para estimar la recarga potencial debida a la precipitación en una zona húmeda tropical, del este de Antioquia (Colombia), que permite cuantificar su variabilidad espacial resultante de los diferentes parámetros hidrometeorológicos y del terreno considerados. Para la implementación del método se sigue un algoritmo basado en la aplicación de un balance hídrico celda a celda sobre una representación digital del área de estudio. Se obtienen resultados de valores de recarga comparables con los estimados mediante algunas ecuaciones empíricas desarrolladas en zonas tropicales

Evaluación del potencial acuífero de los municipios de Puerto Berrío y Puerto Nare.

Se presenta el análisis del potencial acuífero de un área de 470 km2 correspondiente a los municipios de Puerto Berrío y Puerto Nare en donde se presenta una demanda importante de agua, que puede ser satisfecha, mediante la explotación del agua subterránea. Según este propósito, se siguío un proceso de recopilación de información, estudio hidrológico, prospección geoélectrica (84 SEV), inventario de puntos de agua, levantamiento geológico y geomorfológico, y estudio de la calidad del agua. Se logro construir un modelo geológico tridimensional de la región, que sirvio de apoyo para todo el trabajo posterior

The ecology of peace : preparing Colombia for new political and planetary climates

ABSTRACT: Colombia, one of the world’s most species-rich nations, is currently undergoing a profound social transition: the end of a decadeslong conflict with the Revolutionary Armed Forces of Colombia, known as FARC. The peace agreement process will likely transform the country’s physical and socioeconomic landscapes at a time when humans are altering Earth’s atmosphere and climate in unprecedented ways. We discuss ways in which these transformative events will act in combination to shape the ecological and environmental future of Colombia. We also highlight the risks of creating perverse development incentives in these critical times, along with the potential benefits – for the country and the world – if Colombia can navigate through the peace process in a way that protects its own environment and ecosystems

Canagliflozin and renal outcomes in type 2 diabetes and nephropathy

BACKGROUND Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium–glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes. METHODS In this double-blind, randomized trial, we assigned patients with type 2 diabetes and albuminuric chronic kidney disease to receive canagliflozin, an oral SGLT2 inhibitor, at a dose of 100 mg daily or placebo. All the patients had an estimated glomerular filtration rate (GFR) of 30 to <90 ml per minute per 1.73 m2 of body-surface area and albuminuria (ratio of albumin [mg] to creatinine [g], >300 to 5000) and were treated with renin–angiotensin system blockade. The primary outcome was a composite of end-stage kidney disease (dialysis, transplantation, or a sustained estimated GFR of <15 ml per minute per 1.73 m2), a doubling of the serum creatinine level, or death from renal or cardiovascular causes. Prespecified secondary outcomes were tested hierarchically. RESULTS The trial was stopped early after a planned interim analysis on the recommendation of the data and safety monitoring committee. At that time, 4401 patients had undergone randomization, with a median follow-up of 2.62 years. The relative risk of the primary outcome was 30% lower in the canagliflozin group than in the placebo group, with event rates of 43.2 and 61.2 per 1000 patient-years, respectively (hazard ratio, 0.70; 95% confidence interval [CI], 0.59 to 0.82; P=0.00001). The relative risk of the renal-specific composite of end-stage kidney disease, a doubling of the creatinine level, or death from renal causes was lower by 34% (hazard ratio, 0.66; 95% CI, 0.53 to 0.81; P<0.001), and the relative risk of end-stage kidney disease was lower by 32% (hazard ratio, 0.68; 95% CI, 0.54 to 0.86; P=0.002). The canagliflozin group also had a lower risk of cardiovascular death, myocardial infarction, or stroke (hazard ratio, 0.80; 95% CI, 0.67 to 0.95; P=0.01) and hospitalization for heart failure (hazard ratio, 0.61; 95% CI, 0.47 to 0.80; P<0.001). There were no significant differences in rates of amputation or fracture. CONCLUSIONS In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years

Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups

Background: Canagliflozin reduces the risk of kidney failure in patients with type 2 diabetes mellitus and chronic kidney disease, but effects on specific cardiovascular outcomes are uncertain, as are effects in people without previous cardiovascular disease (primary prevention). Methods: In CREDENCE (Canagliflozin and Renal Events in Diabetes With Established Nephropathy Clinical Evaluation), 4401 participants with type 2 diabetes mellitus and chronic kidney disease were randomly assigned to canagliflozin or placebo on a background of optimized standard of care. Results: Primary prevention participants (n=2181, 49.6%) were younger (61 versus 65 years), were more often female (37% versus 31%), and had shorter duration of diabetes mellitus (15 years versus 16 years) compared with secondary prevention participants (n=2220, 50.4%). Canagliflozin reduced the risk of major cardiovascular events overall (hazard ratio [HR], 0.80 [95% CI, 0.67-0.95]; P=0.01), with consistent reductions in both the primary (HR, 0.68 [95% CI, 0.49-0.94]) and secondary (HR, 0.85 [95% CI, 0.69-1.06]) prevention groups (P for interaction=0.25). Effects were also similar for the components of the composite including cardiovascular death (HR, 0.78 [95% CI, 0.61-1.00]), nonfatal myocardial infarction (HR, 0.81 [95% CI, 0.59-1.10]), and nonfatal stroke (HR, 0.80 [95% CI, 0.56-1.15]). The risk of the primary composite renal outcome and the composite of cardiovascular death or hospitalization for heart failure were also consistently reduced in both the primary and secondary prevention groups (P for interaction >0.5 for each outcome). Conclusions: Canagliflozin significantly reduced major cardiovascular events and kidney failure in patients with type 2 diabetes mellitus and chronic kidney disease, including in participants who did not have previous cardiovascular disease

Design and baseline characteristics of the finerenone in reducing cardiovascular mortality and morbidity in diabetic kidney disease trial

Background: Among people with diabetes, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality and progression of their underlying kidney disease. Finerenone is a novel, nonsteroidal, selective mineralocorticoid receptor antagonist that has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD) while revealing only a low risk of hyperkalemia. However, the effect of finerenone on CV and renal outcomes has not yet been investigated in long-term trials. Patients and Methods: The Finerenone in Reducing CV Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial aims to assess the efficacy and safety of finerenone compared to placebo at reducing clinically important CV and renal outcomes in T2D patients with CKD. FIGARO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven trial running in 47 countries with an expected duration of approximately 6 years. FIGARO-DKD randomized 7,437 patients with an estimated glomerular filtration rate >= 25 mL/min/1.73 m(2) and albuminuria (urinary albumin-to-creatinine ratio >= 30 to <= 5,000 mg/g). The study has at least 90% power to detect a 20% reduction in the risk of the primary outcome (overall two-sided significance level alpha = 0.05), the composite of time to first occurrence of CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure. Conclusions: FIGARO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of CV and renal events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen. Trial Registration: EudraCT number: 2015-000950-39; ClinicalTrials.gov identifier: NCT02545049